The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

por Waters, David, Schwartz, Gregory G, Olsson, Anders G
Publicado 2001

Evolving targets for lipid-modifying therapy

por Do, Rose Q, Nicholls, Stephen J, Schwartz, Gregory G
Publicado 2014

Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study

por Zamani, Payman, Schwartz, Gregory G., Olsson, Anders G., Rifai, Nader, Bao, Weihang, Libby, Peter, Ganz, Peter, Kinlay, Scott
Publicado 2013

Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease

por Kovach, Christopher P., Mesenbring, Elise C., Gupta, Prerna, Glorioso, Thomas J., Ho, P. Michael, Waldo, Stephen W., Schwartz, Gregory G.
Publicado 2023

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

por Mohammadi, Kusha A., Brackin, Taylor, Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Manvelian, Garen, Pordy, Robert, Fazio, Sergio, Geba, Gregory P.
Publicado 2023

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

por Koenig, Wolfgang, Ray, Kausik K., Landmesser, Ulf, Leiter, Lawrence A., Schwartz, Gregory G., Wright, R. Scott, Conde, Lorena Garcia, Han, Jackie, Raal, Frederick J.
Publicado 2023

Effect of alirocumab on cataracts in patients with acute coronary syndromes

por Suc, Gaspard, Schwartz, Gregory G., Goodman, Shaun G., Jukema, J. Wouter, Manvelian, Garen, Poulouin, Yann, Pordy, Robert, Scemama, Michel, Szarek, Michael, Steg, Ph. Gabriel
Publicado 2023

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

por Suc, Gaspard, Schwartz, Gregory G., Goodman, Shaun G., Jukema, J. Wouter, Manvelian, Garen, Poulouin, Yann, Pordy, Robert, Scemama, Michel, Szarek, Michael, Steg, Ph.Gabriel
Publicado 2023

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

por Ray, Kausik K, Kallend, David, Leiter, Lawrence A, Raal, Frederick J, Koenig, Wolfgang, Jaros, Mark J, Schwartz, Gregory G, Landmesser, Ulf, Garcia Conde, Lorena, Wright, R Scott
Publicado 2022

Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial

por Murphy, William A., Lin, Nan, Damask, Amy, Schwartz, Gregory G., Steg, P. Gabriel, Szarek, Michael, Banerjee, Poulabi, Fazio, Sergio, Manvelian, Garen, Pordy, Robert, Shuldiner, Alan R., Paulding, Charles
Publicado 2022

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

por Koomen, Jeroen V., Heerspink, Hiddo J. L., Schrieks, Ilse C., Schwartz, Gregory G., Lincoff, A. Michael, Nicholls, Stephen J., Svensson, Anders, Wedel, Hans, Weichert, Arlette, Grobbee, Diederick E., Stevens, Jasper
Publicado 2019

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

por Nicholls, Stephen J., Schwartz, Gregory G., Buhr, Kevin A., Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Toth, Peter P., Wong, Norman, Sweeney, Michael, Ray, Kausik K.
Publicado 2021

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

por Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Bhatt, Deepak L., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Loy, Megan, Manvelian, Garen, Pordy, Robert, White, Harvey D., Steg, Philippe Gabriel
Publicado 2021

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical...

por Schwartz, Gregory G., Nicholls, Stephen J., Toth, Peter P., Sweeney, Michael, Halliday, Christopher, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Ginsberg, Henry N., Ray, Kausik K.
Publicado 2021

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascu...

por Grobbee, Esmée J., de Jong, Vivian D., Schrieks, Ilse C., Tushuizen, Maarten E., Holleboom, Adriaan G., Tardif, Jean-Claude, Lincoff, A. Michael, Schwartz, Gregory G., Castro Cabezas, Manuel, Grobbee, Diederick E.
Publicado 2022

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSE...

por Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Kim, Yong-Un, Jukema, J. Wouter, Pordy, Robert, Roe, Matthew T., White, Harvey D., Bhatt, Deepak L.
Publicado 2020

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

por Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott
Publicado 2022

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692

por Inzucchi, Silvio E., Viscoli, Catherine M., Young, Lawrence H., Furie, Karen L., Gorman, Mark, Lovejoy, Anne M., Dagogo-Jack, Samuel, Ismail-Beigi, Faramarz, Korytkowski, Mary T., Pratley, Richard E., Schwartz, Gregory G., Kernan, Walter N.
Publicado 2017

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and modera...

por Toth, Peter P., Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Szarek, Michael, Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman C.W., Sweeney, Michael, Ray, Kausik K.
Publicado 2022

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

por Goodman, Shaun G., Steg, Philippe Gabriel, Poulouin, Yann, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Garon, Genevieve, Harrington, Robert A., Jukema, J. Wouter, Manvelian, Garen, Stipek, Wanda, Szarek, Michael, White, Harvey D., Schwartz, Gregory G.
Publicado 2023